6 withdrawn. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Withdrawn 6 |
| Phase 1 | 2 | Withdrawn 2 |
Follow Deglutition Disorders: new trials by email Literature Review of Deglutition Disorders trials Research Report on Deglutition Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery Esomeprazole, Placebo Oral Tablet - Dysphagia, GERD | Phase 2 | Withdrawn | Icahn School of Medicine at Mount Sinai | 2020-07-01 | 2020-11-23 | |
| Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose Trehalose - Oculopharyngeal Muscular Dystrophy | Phase 2 | Withdrawn | Bioblast Pharma Ltd. | 2017-06-15 | 2020-01-13 | |
| CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve - Mitral Valve Regurgitation | Phase 1 / Phase 2 | Withdrawn | Edwards Lifesciences | 2016-11-01 | 2018-01-09 | |
| Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis dexlansoprazole - Gastroesophageal Reflux Disease, Eosinophilic Esophagitis | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2012-03-01 | 2012-04-19 | |
| Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus HANAROSTENT TM covered Esophageal Stent - Esophageal Cancer | Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2010-11-01 | 2015-06-03 | |
| Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD EsophyX™ system with SerosaFuse fasteners - Gastroesophageal Reflux Disease (GERD) | Phase 2 | Withdrawn | University of Alberta | 2010-01-01 | 2015-04-29 |
Gastroesophageal Reflux (4) · Eosinophilic Esophagitis (1) · Esophageal Neoplasms (1) · Joint Diseases (1) · Lymphoma, Follicular (1) · Mitral Valve Insufficiency (1) · Muscular Dystrophy, Oculopharyngeal (1) · Neoplasm Metastasis (1) · Neoplasms (1)
Digestive System Diseases (6) · Esophageal Diseases (6) · Gastrointestinal Diseases (6) · Esophageal Motility Disorders (4) · Otorhinolaryngologic Diseases (4) · Pharyngeal Diseases (4) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Musculoskeletal Diseases (2) · Cardiovascular Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Neoplasms (1) · Eosinophilia (1) · Esophagitis (1)
Dexlansoprazole (1) · Esomeprazole (1) · Trehalose (1)
Bioblast Pharma Ltd. (1) · Edwards Lifesciences (1) · Icahn School of Medicine at Mount Sinai (1) · Mayo Clinic (1) · University of Alberta (1) · Weill Medical College of Cornell University (1)
Canada (3) · United States (2) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Switzerland (1)
Andrew C Hecht, MD (1) · Bernard Brais, MD (1) · Jeffrey A Alexander, MD (1) · Lars Sondergaard (1) · Michel Kahaleh, M.D. (1)